Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens
Despite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirab...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Online |
| Jazyk: | angličtina |
| Vydáno: |
Frontiers Media SA
2021
|
| Témata: | |
| On-line přístup: | 18353 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1865100012370788352 |
|---|---|
| author | Magdalena Plebanski Eric J. Gowans Peter Smooker Shuo Li |
| author_browse | Eric J. Gowans Magdalena Plebanski Peter Smooker Shuo Li |
| author_facet | Magdalena Plebanski Eric J. Gowans Peter Smooker Shuo Li |
| author_sort | Magdalena Plebanski |
| collection | Directory of Open Access Books |
| description | Despite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirable. There are no vaccines available for HIV, HCV and Malaria, and all attempts to make a broadly effective vaccine have failed so far. In this Research Topic we look into why vaccines have failed over the years, and what we have learn from these attempts. Rather than only showing positive results, this issue aims to reflect on failed efforts in vaccine development. Coming to understand our limitations will have theoretical and practical implications for the future development of vaccines to these major global disease burdens. |
| format | Online |
| id | doab-20.500.12854ir-62680 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-626802024-03-30T23:21:30Z Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens Magdalena Plebanski Eric J. Gowans Peter Smooker Shuo Li R5-920 RC581-607 QR1-502 Q1-390 influenza HIV Malaria Infectious Disease Genetics Vaccine HCV immunology thema EDItEUR::M Medicine and Nursing Despite continuous progress in the development of anti-viral and anti-bacterial/parasite drugs, the high cost of medicines and the potential for re-infection, especially in high risk groups, suggest that protective vaccines to some of the most dangerous persistent infections are still highly desirable. There are no vaccines available for HIV, HCV and Malaria, and all attempts to make a broadly effective vaccine have failed so far. In this Research Topic we look into why vaccines have failed over the years, and what we have learn from these attempts. Rather than only showing positive results, this issue aims to reflect on failed efforts in vaccine development. Coming to understand our limitations will have theoretical and practical implications for the future development of vaccines to these major global disease burdens. 2021-02-12T08:35:22Z 2021-02-12T08:35:22Z 2016-01-19 14:05:46 2016 book 18353 16648714 9782889199662 https://directory.doabooks.org/handle/20.500.12854/62680 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Why_Vaccines_to_HIV_HCV_and_Malaria_Have_So_Far_Failed_-_Challenges_to_Developing_Vaccines_against_/997 http://journal.frontiersin.org/researchtopic/2072/why-vaccines-to-hiv-hcv-and-malaria-have-so-far-failed---challenges-to-developing-vaccines-against-i Frontiers Media SA 10.3389/978-2-88919-966-2 10.3389/978-2-88919-966-2 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889199662 157 open access |
| spellingShingle | R5-920 RC581-607 QR1-502 Q1-390 influenza HIV Malaria Infectious Disease Genetics Vaccine HCV immunology thema EDItEUR::M Medicine and Nursing Magdalena Plebanski Eric J. Gowans Peter Smooker Shuo Li Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
| title | Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
| title_full | Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
| title_fullStr | Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
| title_full_unstemmed | Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
| title_short | Why vaccines to HIV, HCV and Malaria have so far failed - Challenges to developing vaccines against immunoregulating pathogens |
| title_sort | why vaccines to hiv hcv and malaria have so far failed challenges to developing vaccines against immunoregulating pathogens |
| topic | R5-920 RC581-607 QR1-502 Q1-390 influenza HIV Malaria Infectious Disease Genetics Vaccine HCV immunology thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC581-607 QR1-502 Q1-390 influenza HIV Malaria Infectious Disease Genetics Vaccine HCV immunology thema EDItEUR::M Medicine and Nursing |
| url | 18353 |
| work_keys_str_mv | AT magdalenaplebanski whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens AT ericjgowans whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens AT petersmooker whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens AT shuoli whyvaccinestohivhcvandmalariahavesofarfailedchallengestodevelopingvaccinesagainstimmunoregulatingpathogens |